Crossmark

Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter

Crossref DOI link: https://doi.org/10.1016/j.nrleng.2020.02.001

Published Print: 2021-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Pato Pato, A.

Costa Arpín, E.

Rodríguez Regal, A.

Rodríguez Constenla, I.

Cimas Hernando, I.

Muñoz Pousa, I.

Naya Ríos, L.

Lorenzo González, J.R.

Amigo Jorrín, M.C.

Prieto González, J.M.
License Information

Text and Data Mining valid from 2021-06-01

Text and Data Mining valid from 2021-06-01

Version of Record valid from 2020-02-08
More Information

This article is maintained by: Elsevier

Article Title: Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter

Journal Title: Neurología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.nrleng.2020.02.001

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.nrl.2018.02.003

Content Type: article

Copyright: © 2018 Sociedad Española de Neurología. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below